Skip to main content
AAO-HNSF 2023 Annual Meeting & OTO Experience Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Rate ePoster

Rhinology/Allergy

(039) Angiofibroma Treatment Evaluation in a Tertiary Center: Recurrences and Complications

Monday, October 2, 2023
2:45 PM – 3:45 PM East Coast USA Time
Has Audio

    Presenting Author(s)

  • Mohsen Naraghi, MD, FARS

    Triple Board Certified Rhinologist and Facial Plastic Surgeon
    RRS
    Jacksonville, FL, United States

    • Co-Author(s)

  • ML

    Maryam Lotfi, MD

    Department of Pathology, TUMS School of Medicine, USA

  • MM

    Mahdokht Manavi, MD

    Otolaryngologist, Head and Neck Surgeon; Rhinology Research Society, USA

Disclosure(s):
Mohsen Naraghi, MD, FARS: No relevant relationships to disclose.


Introduction: This article retrospectively analyzed and discussed patients who have undergone surgery in the past 10 years in a university referral center.

Methods: A cross-sectional retrospective study was carried out using data from a review of the medical records of one hundred twenty male patients with histologically confirmed as having JNA, who underwent surgery in a referral university hospital between 2010 and 2020, which were retrospectively reviewed.

Results: Pre-operative embolization was performed in 52.5 % of cases with a median of 2 days before surgery. There was no significant relationship between embolization and tumor recurrence (p=0.806). No residues were detected in 88.3 % of patients. The most common sites for tumor residue were intracranial sites (cavernous sinus, carotid artery) with 35.7 % of cases. The other sites were pterygopalatine fossa in 14.3 %, sino-nasal residue in 14.3%, skull base residue in 14.3 %, para-pharynx in 7.1 %, petrous bone in 7.1 % and retro-pharynx in 7.1 %. There was a trend towards tumor residue in higher stages. Involved anatomic locations of angiofibromas in patients with recurrence were sphenopalatine region in 3, orbit in 2, infratemporal fossa in 4, skull base in 5, and middle cranial fossa in 6.

Conclusions: The recurrence rate was associated with the advanced tumor stage at the time of diagnosis and intracranial extension of the tumor. All patients with intracranial involvement should be followed more closely. Preoperative selective arterial embolization is used to reduce bleeding during surgery, but it has nothing to do with tumor recurrence rate.